文献速递肝病

非选择性β受体阻滞剂治疗改善晚期慢性肝病系统性炎症并改善临床结局

Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
PubMed 文献 · Gut · 2020-11-16

本研究纳入307例晚期慢性肝病患者,在连续肝静脉压力梯度测量中评估非选择性β受体阻滞剂(NSBB)对系统性炎症标志物的影响及其与临床结局的关系。结果显示NSBB治疗可降低白细胞计数和C反应蛋白,尤其在Child-C级患者中更明显,且不依赖HVPG应答。NSBB相关白细胞计数下降≥15%与失代偿患者进一步失代偿风险降低及整体患者肝病相关死亡风险降低独立相关。

要点

  • NSBB治疗可降低晚期慢性肝病患者白细胞计数和C反应蛋白,Child-C级患者更显著。
  • NSBB相关白细胞计数下降≥15%与失代偿患者进一步失代偿风险降低独立相关。
  • NSBB相关白细胞计数下降≥15%与整体患者肝病相关死亡风险降低独立相关。

核心结论

  • NSBB治疗似乎具有全身抗炎活性,表现为白细胞计数和C反应蛋白水平降低。
  • 该效应在Child-C级患者中最明显,且不依赖于HVPG应答。
  • NSBB相关白细胞计数下降≥15%与进一步失代偿和死亡风险降低相关。

研究设计与样本

  • 研究纳入307例稳定晚期慢性肝病患者,Child-A级77例(25.1%)、Child-B级161例(52.4%)、Child-C级69例(22.5%),中位HVPG为20(IQR 17-24)mm Hg,其中231例(75.2%)为失代偿期。
  • 在未使用NSBB和稳定使用NSBB时连续测量HVPG,同时检测系统性炎症标志物包括白细胞计数、C反应蛋白、白介素-6和降钙素原。
  • 采用竞争风险回归分析NSBB相关系统性炎症变化对失代偿和肝病相关死亡风险的影响。

主要发现

  • 整体队列中,启动NSBB治疗后白细胞计数显著下降(中位数变化:-2%(IQR -19;+13),p=0.011)。
  • NSBB相关白细胞计数降低在Child-C级为-16%(-30;+3)%、Child-B级为-2%(-16;+16)%、Child-A级为+3%(-7;+13)%,p<0.001;C反应蛋白降低在Child-C级为-26%(-56,+8)%、Child-B级为-16%(-46;+13)%、Child-A级为±0(-33;+33)%,p<0.001。
  • NSBB相关白细胞计数变化与C反应蛋白变化(Spearman's ρ=0.228,p<0.001)、降钙素原变化(ρ=0.470,p=0.002)和白介素-6变化(ρ=0.501,p=0.001)相关,但与HVPG变化无关(ρ=0.097,p=0.088)。
  • NSBB相关系统性炎症下降(即白细胞计数降低≥15%)见于91例(29.6%)患者,为失代偿患者进一步失代偿的独立保护因素(sHR:0.694(0.49-0.98),p=0.038),也是整体患者肝病相关死亡的独立保护因素(sHR:0.561(0.356-0.883),p=0.013)。

临床怎么用

  • 对于晚期慢性肝病患者,启动NSBB治疗后可监测白细胞计数和C反应蛋白等系统性炎症标志物变化。
  • NSBB相关白细胞计数下降≥15%可能提示进一步失代偿和肝病相关死亡风险降低,不依赖HVPG应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic inflammation promotes the development of clinical events in patients with advanced chronic liver disease (ACLD). We assessed whether (1) non-selective beta blocker (NSBB) treatment initiation impacts biomarkers of systemic inflammation and (2) whether these changes in systemic inflammation predict complications and mortality. DESIGN: Biomarkers of systemic inflammation, that is, white blood cell count (WBC), C reactive protein (CRP), interleukin-6 (IL-6) and procalcitonin (PCT) were determined at sequential hepatic venous pressure gradient (HVPG) measurements without NSBB and under stable NSBB intake. The influence of NSBB-related changes in systemic inflammation on the risk of decompensation and liver-related death was analysed using competing risk regression. RESULTS: Our study comprised 307 stable patients with ACLD (Child-A: 77 (25.1%), Child-B: 161 (52.4%), Child-C: 69 (22.5%), median HVPG: 20 (IQR 17-24) mm Hg) including 231 (75.2%) with decompensated disease.WBC significantly decreased upon NSBB therapy initiation (median: -2 (IQR -19;+13)%, p=0.011) in the overall cohort. NSBB-related reductions of WBC (Child-C: -16 (-30;+3)% vs Child-B: -2 (-16;+16)% vs Child-A: +3 (-7;+13)%, p<0.001) and of CRP (Child-C: -26 (-56,+8)% vs Child-B: -16 (-46;+13)% vs Child-A: ±0 (-33;+33)%, p<0.001) were more pronounced in advanced stages of cirrhosis. The NSBB-associated changes in WBC correlated with changes in CRP (Spearman's ρ=0.228, p<0.001), PCT (ρ=0.470, p=0.002) and IL-6 (ρ=0.501, p=0.001), but not with changes in HVPG (ρ=0.097, p=0.088).An NSBB-related decrease in systemic inflammation (ie, WBC reduction ≥15%) was achieved by n=91 (29.6%) patients and was found to be an independent protective factor of further decompensation (subdistribution HR, sHR: 0.694 (0.49-0.98), p=0.038) in decompensated patients and of liver-related mortality in the overall patient cohort (sHR: 0.561 (0.356-0.883), p=0.013). CONCLUSION: NSBB therapy seems to exert systemic anti-inflammatory activity as evidenced by reductions of WBC and CRP levels. Interestingly, this effect was most pronounced in Child-C and independent of HVPG response. An NSBB-related WBC reduction by ≥15% was associated with a decreased risk of further decompensation and death.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Jachs M, Hartl L, Schaufler D, et al. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut. 2020. PMID: 33199442. doi:10.1136/gutjnl-2020-322712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。